Baseline demographics and disease characteristics
| . | Dinaciclib (n = 20) . | Ofatumumab (n = 22) . | Total (n = 42) . |
|---|---|---|---|
| Sex (male) | 15 (75.0) | 17 (77.3) | 32 (76.2) |
| Age, mean ± SD, y | 60.1 ± 8.6 | 62.3 ± 9.1 | 61.2 ± 8.8 |
| Race | |||
| White | 19 (95.0) | 20 (90.9) | 39 (92.9) |
| Other | 1 (5.0) | 2 (9.0) | 3 (7.2) |
| Rai stage | |||
| I | 1 (5.0) | 2 (9.1) | 3 (7.1) |
| II | 4 (20.0) | 8 (36.4) | 12 (28.6) |
| III | 1 (5.0) | 5 (22.7) | 6 (14.3) |
| IV | 13 (65.0) | 7 (31.8) | 20 (47.6) |
| Missing | 1 (5.0) | 0 (0.0) | 1 (2.4) |
| Number of prior therapies, median (range) | 2 (1-6) | 3 (1-20) | 3 (1-20) |
| Prior fludarabine | 18 (90.0) | 21 (95.5) | 39 (92.9) |
| Prior rituximab | 19 (95.0) | 22 (100.0) | 41 (97.6) |
| Bulky disease* | 12 (60.0) | 12 (54.5) | 24 (57.1) |
| ECOG <1 | 18 (90.0) | 22 (100.0) | 40 (95.2) |
| Del17p | 7 (35.0) | 9 (40.9) | 16 (38.1) |
| Refractory/relapse | |||
| Chemoimmunotherapy ≤6 mo | 14 (70.0) | 13 (59.1) | 27 (64.3) |
| Fludarabine refractory | 3 (15.0) | 3 (13.6) | 6 (14.3) |
| Chemoimmunotherapy >6 to 24 mo | 3 (15.0) | 6 (27.3) | 9 (21.4) |
| . | Dinaciclib (n = 20) . | Ofatumumab (n = 22) . | Total (n = 42) . |
|---|---|---|---|
| Sex (male) | 15 (75.0) | 17 (77.3) | 32 (76.2) |
| Age, mean ± SD, y | 60.1 ± 8.6 | 62.3 ± 9.1 | 61.2 ± 8.8 |
| Race | |||
| White | 19 (95.0) | 20 (90.9) | 39 (92.9) |
| Other | 1 (5.0) | 2 (9.0) | 3 (7.2) |
| Rai stage | |||
| I | 1 (5.0) | 2 (9.1) | 3 (7.1) |
| II | 4 (20.0) | 8 (36.4) | 12 (28.6) |
| III | 1 (5.0) | 5 (22.7) | 6 (14.3) |
| IV | 13 (65.0) | 7 (31.8) | 20 (47.6) |
| Missing | 1 (5.0) | 0 (0.0) | 1 (2.4) |
| Number of prior therapies, median (range) | 2 (1-6) | 3 (1-20) | 3 (1-20) |
| Prior fludarabine | 18 (90.0) | 21 (95.5) | 39 (92.9) |
| Prior rituximab | 19 (95.0) | 22 (100.0) | 41 (97.6) |
| Bulky disease* | 12 (60.0) | 12 (54.5) | 24 (57.1) |
| ECOG <1 | 18 (90.0) | 22 (100.0) | 40 (95.2) |
| Del17p | 7 (35.0) | 9 (40.9) | 16 (38.1) |
| Refractory/relapse | |||
| Chemoimmunotherapy ≤6 mo | 14 (70.0) | 13 (59.1) | 27 (64.3) |
| Fludarabine refractory | 3 (15.0) | 3 (13.6) | 6 (14.3) |
| Chemoimmunotherapy >6 to 24 mo | 3 (15.0) | 6 (27.3) | 9 (21.4) |
Data are presented as n (%) of patients, unless otherwise indicated.
ECOG, Eastern Cooperative Oncology Group.
Defined as any lymph node >5 cm by physical exam or computed tomography scan.